| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5594490 | American Heart Journal | 2017 | 9 Pages |
Abstract
The SHIELD-2 trial was statistically underpowered due to early trial termination and did not meet its primary objective. Despite this limitation, azimilide showed promise as a safe and effective drug in reducing all-cause shocks, unplanned hospitalizations, and ED visits in ICD patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Victoria M. MBChB, David B. MD, PhD, Kenneth W. MD, Paul MD, Peter R. MD, SHIELD-2 Investigators SHIELD-2 Investigators,